June 21 (Reuters) - Eli Lilly and Co LLY.N:
LILLY'S ORAL GLP-1, ORFORGLIPRON, SHOWED COMPELLING EFFICACY AND A SAFETY PROFILE CONSISTENT WITH INJECTABLE GLP-1 MEDICINES, IN COMPLETE PHASE 3 RESULTS PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE
ELI LILLY AND CO - ORFORGLIPRON LOWERS A1C BY 1.3% TO 1.6% IN PHASE 3 TRIAL
ELI LILLY AND CO - REMAINS ON TRACK TO SUBMIT ORFORGLIPRON FOR WEIGHT MANAGEMENT BY END OF YEAR
Source text: ID:nPn2MPJ9Ka
Further company coverage: LLY.N
((Reuters.Briefs@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。